A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.

ABSTRACT: Shiga toxin-producing Escherichia coli infections are difficult to treat due to the risk of antibiotic-induced stress upregulating the production of toxins, medical treatment is consequently limited to supportive care to prevent the development of hemolytic uremic syndrome (HUS). Here, we introduce a potentially therapeutic humanized mouse monoclonal antibody (Hu-mAb 2-5) targeting Stx2a, the most common Shiga toxin subtype identified from outbreaks. We demonstrate that Hu-mAb 2-5 has low immunogenicity in healthy adults ex vivo and high neutralizing efficacy in vivo, protecting mice from mortality and HUS-related tissue damage.

SUBMITTER: Kirkland ME 

PROVIDER: S-EPMC10777836 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature